# AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

Study · id `cardio:ct-nct07030595` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07030595](<https://clinicaltrials.gov/study/NCT07030595>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07030595

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 474 participants.

## Technical summary

Registry record NCT07030595. Randomized; no masking; primary purpose treatment. Start 2023-06-12 (actual); primary completion 2024-10-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 474 participants (enrolled count; ClinicalTrials.gov record NCT07030595, source copy `cardio:ctgov-nct07030595-2025-11-17`, retrieved 2026-10-26)
- Started: 2023-06-12 (actual) (ClinicalTrials.gov record NCT07030595, source copy `cardio:ctgov-nct07030595-2025-11-17`, retrieved 2026-10-26)
- Primary completion: 2024-10-02 (actual) (ClinicalTrials.gov record NCT07030595, source copy `cardio:ctgov-nct07030595-2025-11-17`, retrieved 2026-10-26)
- Completion: 2025-05-30 (actual) (ClinicalTrials.gov record NCT07030595, source copy `cardio:ctgov-nct07030595-2025-11-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07030595, source copy `cardio:ctgov-nct07030595-2025-11-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07030595-2025-11-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
- Acronym: RESPOND-1
- Condition: ESRD (End Stage Renal Disease)
- Condition: Chronic Kidney Disease(CKD)
- Condition: Hyperphosphatemia
- Condition: Hyperphosphatemia in Chronic Kidney Disease
- Condition: Dialysis
- Condition: Chronic Kidney Disease, Receiving Dialysis
- Intervention (Drug): AP301
- Intervention (Drug): Sevelamer carbonate (Renvela®)
- Intervention (Drug): AP301 Low Dose
- Lead sponsor: Alebund Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 275d49ea3c969f1f6026e3bcc6d17c5d8e285bb4755a1e80b751f0ef57459366
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
